Pipeline & Development Strategy

Our company is advancing a programmable long-acting therapeutic platform through a staged development strategy designed to support clinical translation:

 

1) Platform validation:
 

Our primary focus is the development and clinical translation of our therapeutic platform, targeting sIBM as muscle-atrophy related orphan indication for fast clinical entry. Current work is aimed at generating the preclinical package needed to support future clinical development.

​

2) Indication strategy
 

In parallel, we are evaluating focused side applications where our platform may offer a clinically efficient path to proof of concept. In particular we are currently exploring defense/military, skin/ cosmetics and aging as target areas for accelerated development.
 

3) Future expansion

Once the platform is validated, its modular design may enable expansion across multiple payloads and therapeutic areas.